CVS Health Corporation $CVS Holdings Decreased by Natixis Advisors LLC

Natixis Advisors LLC reduced its stake in shares of CVS Health Corporation (NYSE:CVS) by 4.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,278,204 shares of the pharmacy operator’s stock after selling 55,533 shares during the quarter. Natixis Advisors LLC’s holdings in CVS Health were worth $101,438,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of CVS. Sei Investments Co. raised its stake in shares of CVS Health by 17.4% during the second quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator’s stock valued at $62,474,000 after purchasing an additional 134,535 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of CVS Health by 1.2% during the second quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator’s stock valued at $77,353,000 after purchasing an additional 13,329 shares in the last quarter. Treasurer of the State of North Carolina raised its stake in shares of CVS Health by 1.3% during the second quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator’s stock valued at $40,358,000 after purchasing an additional 7,588 shares in the last quarter. HUB Investment Partners LLC raised its stake in shares of CVS Health by 25.0% during the second quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator’s stock valued at $1,039,000 after purchasing an additional 3,011 shares in the last quarter. Finally, Alliancebernstein L.P. raised its stake in shares of CVS Health by 8.0% during the second quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator’s stock valued at $111,017,000 after purchasing an additional 119,439 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors.

CVS Health Trading Down 1.0%

Shares of CVS opened at $89.70 on Wednesday. The business’s 50-day moving average price is $82.44 and its 200 day moving average price is $79.64. The stock has a market capitalization of $114.45 billion, a P/E ratio of 39.51, a P/E/G ratio of 0.89 and a beta of 0.62. CVS Health Corporation has a 1-year low of $58.50 and a 1-year high of $98.43. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.CVS Health’s revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the business posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Analysts expect that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were paid a $0.665 dividend. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 3.0%. CVS Health’s dividend payout ratio (DPR) is currently 117.18%.

Insider Transactions at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the transaction, the director directly owned 6,213,261 shares in the company, valued at $586,842,501.45. This represents a 24.20% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 3,441,551 shares of company stock worth $323,703,977 in the last three months. 0.85% of the stock is currently owned by company insiders.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Truist raised its price target on CVS Health to $108 from $102 and kept a Buy rating, signaling continued upside potential for the shares. Article Title
• Positive Sentiment: CVS was highlighted by Zacks as a strong value stock and a name attracting investor attention, which can reinforce bullish sentiment around the shares. Article Title
• Positive Sentiment: CVS Health is leveraging AI in pharmacy dispensing, suggesting efficiency gains and a push to improve operations over time. Article Title
• Neutral Sentiment: CVS published a company update about helping seniors navigate digital-first health care, which is positive for its brand but not likely to move the stock on its own. Article Title
• Neutral Sentiment: Market commentary noted CVS is attracting investor attention and compared its dividend profile with UnitedHealth, but this was largely discussion-oriented rather than a new catalyst. Article Title
• Negative Sentiment: CVS faces a lawsuit alleging it pocketed $250 million in drug savings meant for uninsured patients, adding legal and reputational overhang. Article Title
• Negative Sentiment: Eli Lilly said it won back CVS Health’s support on GLP-1 access, reversing Novo Nordisk’s advantage; the headline is more about Lilly, but it suggests CVS is still central to intense pricing and access battles in weight-loss drugs. Article Title

Wall Street Analysts Forecast Growth

CVS has been the topic of several research reports. Wolfe Research dropped their price target on shares of CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a research report on Monday, March 2nd. Royal Bank Of Canada boosted their price target on shares of CVS Health from $93.00 to $107.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Morgan Stanley boosted their price target on shares of CVS Health from $93.00 to $106.00 and gave the stock an “overweight” rating in a research report on Thursday, May 14th. Wall Street Zen upgraded shares of CVS Health from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Leerink Partners reiterated an “outperform” rating and issued a $98.00 price target on shares of CVS Health in a research report on Thursday, March 5th. Twenty-two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.68.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.